Production (Stage)
Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.00060.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -2.06M | -2.06M | -2.17M | -2.17M | -- |
| Total Depreciation and Amortization | 33.10K | 33.10K | 30.40K | 30.40K | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 773.40K | 773.40K | 320.90K | 320.90K | -- |
| Change in Net Operating Assets | -202.50K | -202.50K | 216.70K | 216.70K | -- |
| Cash from Operations | -1.45M | -1.45M | -1.60M | -1.60M | -- |
| Capital Expenditure | -51.50K | -51.50K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00 | 0.00 | 100.00 | 100.00 | -- |
| Other Investing Activities | -6.40K | -6.40K | 300.00 | 300.00 | -- |
| Cash from Investing | -58.00K | -58.00K | 300.00 | 300.00 | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -32.40K | -32.40K | -36.50K | -36.50K | -- |
| Issuance of Common Stock | 2.36M | 2.36M | 1.32M | 1.32M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -336.50K | -336.50K | -28.20K | -28.20K | -- |
| Cash from Financing | 2.00M | 2.00M | 1.26M | 1.26M | -- |
| Foreign Exchange rate Adjustments | -15.80K | -15.80K | 10.10K | 10.10K | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 466.60K | 466.60K | -334.10K | -334.10K | -- |